From L-R: Arda Therapeutics Chief Technology Officer Remi-Martin Laberge, CEO Adam Freund and CSO Scott Turner
October 8, 2024 07:30 AM EDTUpdated 12:28 PM
Financing
Startups

Ex­clu­sive: Lil­ly backs a16z-fund­ed Ar­da Ther­a­peu­tic­s' $43M Se­ries A to take AD­Cs in­to fi­bro­sis

Kyle LaHucik

Senior Reporter

A three-year-old start­up based on decades of re­search in cell de­ple­tion is bet­ting that some of the hottest tools in on­col­o­gy may work even bet­ter …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pfiz­er's for­mer top ex­ec­u­tives pitched changes to board as part of ac­tivist's plan

Sage faces third study fail in six months as Alzheimer's can­di­date miss­es Phase 2 goal

Astel­las places new bet on gene ther­a­py in $50M up­front deal with UK start­up

Ex­clu­sive: Tiny start­up with big vi­sion to ex­tend healthspan by 20 years says it dis­cov­ered an ‘At­las of ...

J&J’s ‘pret­zel’ drug-de­vice ther­a­py fails in cer­tain blad­der can­cer pa­tients

Mer­ck part­ners with small UK biotech to drug fi­brob­lasts for fi­bro­sis, I&I dis­eases

A service from the Financial Times